AUSTRALIA - CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA

Published Jul 21, 2015
London, UK - Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires approval from the Pharmaceutical Benefits Advisory Committee (PBAC), for whom value for money must be demonstrated. The full study, “How Data Packages Lacking Phase III Pivotal Trial Data can Support Regulatory Approval and Reimbursement for Oncologics in Australia,” was published in Value in Health Regional Issues focusing on Asia, Volume 6. In Australia, if Phase 2 trials indicate potentially substantial clinical benefits over the relevant comparator, regulatory approval and public reimbursement can be achieved for oncology drugs without requiring supportive Phase 3 trial data. The study objective is to determine whether and under what circumstances oncology drugs lacking comparative Phase 3 data can achieve regulatory approval and public reimbursement in Australia. Publically available documentation for 6 oncology drugs TGA-appraised without Phase 3 data were extracted, 5 of which obtained regulatory approval. The EMA and FDA (corresponding regulators in Europe and USA) issued recommendations on these indications an average of 1 and 2 years earlier, respectively. PBAC appraised 6 oncology drugs on such a data package, four recommended for public reimbursement and two rejected. “As we have previously shown for Europe and America, in Australia, early regulatory and reimbursement approval can be achieved for oncology drugs without Phase 3 data. However, both the EMA and FDA appear to make more drugs available, earlier in their developmental pathway, on this basis” says Richard Macaulay, PhD, Senior Consultant of PAREXEL International.

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×